Lyra therapeutics inc - qtrly loss per share $0.56

Lyra therapeutics reports second quarter 2020 financial results and provides corporate update.lyra therapeutics inc - on track to report topline phase 2 results for lyr-210 in chronic rhinosinusitis in 4q 2020.lyra therapeutics inc - qtrly loss per share $0.56.
LYRA Ratings Summary
LYRA Quant Ranking